The latecomers of the hepatitis B treatment Vemlidy that entered the market this year are focusing on their price competitiveness to occupy more shares of the market.

Companies that had already reduced their price upon entry are also seemingly holding in check their competitors' prices.

According to industry sources on the 29th, Daewoong Pharmaceutical reduced its insurance price ceiling for Vemliver Tab. (tenofovir ala fenamide hemitartar hydrochloride) from KRW 2,828 to KRW 2,473 from June.

This is only 3 months after the drug was listed for reimbursement in March. Daewoong Pharmaceutical's voluntary price cuts are interpreted as being conscious of its competitors. Daewo